Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-08-2019 | Computed Tomography | Original Article

Lesion detection by [⁸⁹Zr]Zr-DFO-girentuximab and [¹⁸F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Authors: Sarah R. Verhoeff, Suzanne C. van Es, Eline Boon, Erik van Helden, Lindsay Angus, Sjoerd G. Elias, Sjoukje F. Oosting, Erik H. Aarntzen, Adrienne H. Brouwers, Thomas C. Kwee, Sandra Heskamp, Otto S. Hoekstra, Henk Verheul, Astrid A. M. van der Veldt, Elisabeth G. E. de Vries, Otto C. Boerman, Winette T. A. van der Graaf, Wim J. G. Oyen, Carla M. L. van Herpen

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2019

Abstract

Purpose

The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [⁸⁹Zr]Zr-DFO-girentuximab-PET/CT and [¹⁸F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model.

Methods

Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [⁸⁹Zr]Zr-DFO-girentuximab-PET/CT and [¹⁸F]FDG-PET/CT at baseline. Scans were independently reviewed and lesions of ≥10 mm and lymph nodes of ≥15 mm at CT were analyzed. For lesions with [⁸⁹Zr]Zr-DFO-girentuximab or [¹⁸F]FDG-uptake visually exceeding background uptake, maximum standardized uptake values (SUV_max) were measured.

Results

A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25–12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [⁸⁹Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT alone: 91% (95%CI: 87–94) versus 56% (95%CI: 50–62, p = 0.001), respectively, and more than CT and [¹⁸F]FDG-PET/CT combined (84% (95%CI:79–88, p < 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone.

Conclusions

The addition of [⁸⁹Zr]Zr-DFO-girentuximab-PET/CT and [¹⁸F]FDG-PET/CT to CT increases lesion detection compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting.

Available only for authorised users

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9. https://doi.org/10.1200/JCO.2008.21.4809.CrossRefPubMed

Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8. https://doi.org/10.1016/s1470-2045(12)70559-4.CrossRefPubMedPubMedCentral

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v58–68. https://doi.org/10.1093/annonc/mdw328.CrossRefPubMed

Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016;17(9):1317–24. https://doi.org/10.1016/s1470-2045(16)30196-6.CrossRefPubMed

Oosterwijk-Wakka JC, Boerman OC, Mulders PF, Oosterwijk E. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013;14(6):11402–23. https://doi.org/10.3390/ijms140611402.CrossRefPubMedPubMedCentral

Grabmaier K, Vissers JL, De Weijert MC, Oosterwijk-Wakka JC, Van Bokhoven A, Brakenhoff RH, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer. 2000;85(6):865–70.CrossRefPubMed

Leibovich BC, Sheinin Y, Lohse CM, Thompson RH, Cheville JC, Zavada J, et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol. 2007;25(30):4757–64. https://doi.org/10.1200/jco.2007.12.1087.CrossRefPubMed

Ambrosetti D, Dufies M, Dadone B, Durand M, Borchiellini D, Amiel J, et al. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma. PLoS ONE. 2018;13(2):e0193477. https://doi.org/10.1371/journal.pone.0193477.CrossRefPubMedPubMedCentral

de Martino M, Klatte T, Seligson DB, LaRochelle J, Shuch B, Caliliw R, et al. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol. 2009;182(2):728–34. https://doi.org/10.1016/j.juro.2009.03.077.CrossRefPubMed

10.

Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9(2):802–11.PubMed

11.

Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int. 2007;100(3):556–60. https://doi.org/10.1111/j.1464-410X.2007.07006.x.CrossRefPubMed

12.

Chamie K, Donin NM, Klöpfer P, et al. Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ariser randomized clinical trial. JAMA Oncol. 2017;3(7):913–20. https://doi.org/10.1001/jamaoncol.2016.4419.CrossRefPubMed

13.

Muselaers CH, Boerman OC, Oosterwijk E, Langenhuijsen JF, Oyen WJ, Mulders PF. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol. 2013;63(6):1101–6. https://doi.org/10.1016/j.eururo.2013.02.022.CrossRefPubMed

14.

Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2013;31(2):187–94. https://doi.org/10.1200/jco.2011.41.2445.CrossRefPubMed

15.

Brouwers AH, Buijs WC, Oosterwijk E, Boerman OC, Mala C, De Mulder PH, et al. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin Cancer Res. 2003;9(10 Pt 2):3953S–60S.PubMed

16.

Safaei A, Figlin R, Hoh CK, Silverman DH, Seltzer M, Phelps ME, et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol. 2002;57(1):56–62.CrossRefPubMed

17.

Liu Y. The place of FDG PET/CT in renal cell carcinoma: value and limitations. Front Oncol. 2016;6:201. https://doi.org/10.3389/fonc.2016.00201.CrossRefPubMedPubMedCentral

18.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.CrossRefPubMed

19.

Vanbelle S. Comparing dependent kappa coefficients obtained on multilevel data. Biom J. 2017;59(5):1016–34. https://doi.org/10.1002/bimj.201600093.CrossRefPubMedPubMedCentral

20.

Shinichi N, Holger S. A general and simple method for obtaining R2 from generalized linear mixed-effects models. Methods Ecol Evol. 2013;4(2):133–42. https://doi.org/10.1111/j.2041-210x.2012.00261.x.CrossRef

21.

Han K-R, Pantuck AJ, Bui MHT, Shvarts O, Freitas DG, Zisman A, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61(2):314–9. https://doi.org/10.1016/s0090-4295(02)02163-5.CrossRefPubMed

22.

Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon Alfa-2b compared with interferon Alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9. https://doi.org/10.1056/NEJMoa003013.CrossRefPubMed

23.

McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014;65(3):577–84. https://doi.org/10.1016/j.eururo.2013.08.012.CrossRefPubMed

24.

van der Vos CS, Koopman D, Rijnsdorp S, Arends AJ, Boellaard R, van Dalen JA, et al. Quantification, improvement, and harmonization of small lesion detection with state-of-the-art PET. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):4–16. https://doi.org/10.1007/s00259-017-3727-z.CrossRefPubMedPubMedCentral

25.

Adibi M, Kenney PA, Thomas AZ, Borregales LD, Nogueras-Gonzalez GM, Wang X, et al. Prediction of pulmonary metastasis in renal cell carcinoma patients with indeterminate pulmonary nodules. Eur Urol. 2016;69(2):352–60. https://doi.org/10.1016/j.eururo.2015.08.053.CrossRefPubMed

26.

Mano R, Vertosick E, Sankin AI, Chevinsky MS, Larish Y, Jakubowski CD, et al. Subcentimeter pulmonary nodules are not associated with disease progression in patients with renal cell carcinoma. J Urol. 2015;193(3):776–82. https://doi.org/10.1016/j.juro.2014.09.020.CrossRefPubMed

27.

Hekman MCH, Rijpkema M, Aarntzen EH, Mulder SF, Langenhuijsen JF, Oosterwijk E, et al. Positron emission tomography/computed tomography with (89)Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion. Eur Urol. 2018;74(3):257–260. https://doi.org/10.1016/j.eururo.2018.04.026.

28.

Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, et al. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med. 2015;56(1):63–9. https://doi.org/10.2967/jnumed.114.144840.CrossRefPubMed

Title: Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
Authors: Sarah R. Verhoeff
Suzanne C. van Es
Eline Boon
Erik van Helden
Lindsay Angus
Sjoerd G. Elias
Sjoukje F. Oosting
Erik H. Aarntzen
Adrienne H. Brouwers
Thomas C. Kwee
Sandra Heskamp
Otto S. Hoekstra
Henk Verheul
Astrid A. M. van der Veldt
Elisabeth G. E. de Vries
Otto C. Boerman
Winette T. A. van der Graaf
Wim J. G. Oyen
Carla M. L. van Herpen
Publication date: 01-08-2019
Publisher: Springer Berlin Heidelberg
Keywords: Computed Tomography
Kidney Cancer
Kidney Cancer
Computed Tomography
Kidney Cancer
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2019
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04358-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Lesion detection by [⁸⁹Zr]Zr-DFO-girentuximab and [¹⁸F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2019

A multiparametric [18F]FDG PET/MRI diagnostic model including imaging biomarkers of the tumor and contralateral healthy breast tissue aids breast cancer diagnosis

Eleanor Mantel, Janet S. Reddin, Gang Cheng, Abass Alavi (Eds): Nuclear Medicine Technology. Review Questions for the Board Examinations, Fifth Edition. Springer International Publishing AG, 2018. ISBN 978-3-319-62499-0

Brain metabolic patterns in patients with suspected non-Alzheimer’s pathophysiology (SNAP) and Alzheimer’s disease (AD): is [18F] FDG a specific biomarker in these patients?

PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment

Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A)

The next era of renal radionuclide imaging: novel PET radiotracers